Taysha Gene Therapies Inc (TSHA) - News Archive

In a significant move reflecting its commitment to talent acquisition and retention, Taysha Gene Therapies, Inc. a clinical-stage biotechnology company dedicated to advancing adeno-associated virus (AAV)-based gene ther...

Taysha Gene Therapies Reinforces Talent Acquisition Strategy with New Stock Option Grants Amid Challenging Market ConditionsIn a strategic move to attract and retain top talent, Taysha Gene Therapies, Inc. (Nasdaq: TSHA...

In a strategic move to bolster its workforce amid ongoing financial challenges, Taysha Gene Therapies, Inc. (Nasdaq: TSHA) has announced an inducement grant for a new employee in conjunction with its efforts to attract...

Taysha Gene Therapies: A Balancing Act Between Talent Acquisition and Financial StrugglesIn the ever-evolving landscape of biotechnology, Taysha Gene Therapies, Inc. (NASDAQ: TSHA) has recently taken center stage for a...

Taysha Gene Therapies, Inc. (NASDAQ: TSHA), a clinical-stage biotechnology company dedicated to advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CN...

Taysha Gene Therapies, a prominent clinical-stage biotechnology company specializing in adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), has made a sig...

Taysha Gene Therapies, a clinical-stage biotech company specializing in gene therapies for severe monogenic diseases of the central nervous system, has recently made significant announcements regarding its operations. O...

In the fast-paced world of pharmaceutical sciences, gene therapies have emerged as a promising field, offering potential solutions for severe monogenic diseases. Among the companies leading the charge in this sector, Ta...

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsDallas-based biotechnology company, Taysha Gene Therapies, Inc. (Nasdaq: TSHA), has recently disclosed the pricing detail...

Taysha Gene Therapies Inc., a leading biotechnology company specializing in gene therapies for CNS diseases, recently announced the commencement of an underwritten public offering of up to $75 million in common stock an...

In this article, we will examine the recent developments and market indicators surrounding Taysha Gene Therapies Inc, a leading company in the field of gene therapy. By analyzing several key articles, including one from...

Rett Syndrome is a rare neurodevelopmental disorder primarily affecting females, characterized by a loss of acquired skills, severe cognitive impairment, motor dysfunction, and autonomic abnormalities. Taysha Gene Thera...

Taysha Gene Therapies Grants Inducement Stock Options as Company Aims to Revolutionize Treatment of Genetic DiseasesDALLAS, June 07, 2024 - Taysha Gene Therapies, a promising biotechnology company specializing in adeno-...

In the pursuit of finding effective treatments for Rett Syndrome, Taysha Gene Therapies has achieved a significant milestone. The company recently announced that the U.S. Food and Drug Administration (FDA) has granted R...

In a recent press release, Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced the grant of stock options to three new employees, totaling 140,000 shares of the company s common stock. This move, made by the Compensati...

In recent updates revealed by Taysha Gene Therapies, the company announces significant progress in its TSHA-102 Clinical Program for Rett Syndrome. Additionally, the company reports a substantial decrease in revenue for...

IntroductionTaysha Gene Therapies, Inc. (Nasdaq: TSHA), a prominent clinical-stage gene therapy company specializing in AAV-based gene therapies for central nervous system (CNS) monogenic diseases, has recently shared a...

In a significant breakthrough for biotechnology, Taysha Gene Therapies has announced that it has successfully dosed a pediatric patient with TSHA-102 under its Phase 1/2 REVEAL trial for Rett Syndrome. As it continues t...

Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial for Rett Syndrome Patients, Including AdolescentsHealth Canada has authorized Taysha Gene Therapies protocol amendment to expand eligi...